Cargando…
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Autores principales: | Qin, Shukui, Li, Jin, Zhong, Haijun, Jin, Chuan, Chen, Lili, Yuan, Xianglin, Fan, Qingxia, Chen, Kehe, Cao, Peiguo, Xiao, Jianjun, Jiang, Da, Zhang, Tao, Zhang, Hongyu, Wang, Xicheng, Wang, Wei, Han, Lin, Wang, Qingyu, Zhu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727148/ https://www.ncbi.nlm.nih.gov/pubmed/36323881 http://dx.doi.org/10.1038/s41416-022-02043-7 |
Ejemplares similares
-
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022) -
The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
por: Ma, Yue, et al.
Publicado: (2023) -
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
por: An, Jusheng, et al.
Publicado: (2023) -
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
por: Ren, Zhenggang, et al.
Publicado: (2022) -
Editorial: Microsatellite and microsatellite instability
por: How-Kit, Alexandre, et al.
Publicado: (2023)